Phaseline

Companies › Creative Medical Technology Holdings

Creative Medical Technology Holdings: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CELZ-201-DDT
Perinatal tissue-derived cells for beta cell regeneration/preservation in Type 1 Diabetes
–Phase 1Chronic Low-back Pain; Type 1 DiabetesJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06053242CELZ-201-DDTPhase 1Chronic Low-back PainOtherJan 2027
NCT05626712CELZ-201-DDTPhase 1Type 1 DiabetesMetabolic and endocrineJan 2027

From the company's SEC filings

Cash of $7m on 2026-09-30; operating cash outflow about $6m a year; runway about 14 months at that burn, to Nov 2027

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.